GlassScriptPhysician profile
Timothy Joseph Souchek
NPI 1194709881
$13,281.26
in general payments reported to CMS, 2019-2025
65 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,254 · 2022: $2,325 · 2023: $3,750 · 2024: $4,429 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,599 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,599.10 |
| Education | $102.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $925.21 | 2021-2025 | Calquence, Lynparza, Tagrisso |
| Daiichi Sankyo INC. | $911.78 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| Novartis Pharmaceuticals Corporation | $895.22 | 2021-2025 | |
| Janssen Biotech, INC. | $790.56 | 2021-2024 | Tecvayli, Darzalex, Carvykti |
| Astellas Pharma US INC | $751.17 | 2021-2024 | Padcev, Xtandi, Xospata |
| Pfizer INC. | $549.18 | 2021-2025 | |
| Exelixis INC. | $462.42 | 2021-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $432.42 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $418.78 | 2021-2024 | |
| Glaxosmithkline, LLC. | $386.61 | 2022-2025 | Zejula, Ojjaara, Jemperli |
| Amgen INC. | $385.72 | 2021-2023 | Lumakras, Blincyto, Kyprolis |
| Genentech USA, INC. | $363.98 | 2021-2024 | Phesgo, Venclexta, Polivy |
| Eisai INC. | $358.08 | 2021-2024 | |
| Seagen INC. | $338.53 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Blueprint Medicines Corporation | $293.83 | 2021-2025 | Ayvakit |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $286.36 | 2021-2024 | Opdivo, Opdualag |
| Pharmaessentia USA Corporation | $280.16 | 2022-2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $279.55 | 2021-2024 | Iclusig, Alunbrig, Fruzaqla |
| Genzyme Corporation | $279.39 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $270.77 | 2021-2024 | |
| Lilly USA, LLC | $249.25 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Alexion Pharmaceuticals, INC. | $216.30 | 2021-2024 | Ultomiris |
| Sobi, INC | $194.28 | 2022-2024 | |
| Incyte Corporation | $192.18 | 2021-2024 | Jakafi, Monjuvi |
| Rigel Pharmaceuticals, INC. | $163.84 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $156.02 | 2021-2023 | Imbruvica, Epkinly |
| Morphosys, US INC. | $145.95 | 2021-2024 | Monjuvi |
| Array Biopharma INC | $138.76 | 2022-2025 | Mektovi, Braftovi, Xalkori |
| Puma Biotechnology, INC. | $137.43 | 2021-2024 | Nerlynx |
| Amag Pharmaceuticals, INC. | $131.24 | 2021-2022 | |
| Celgene Corporation | $127.11 | 2023-2024 | Reblozyl |
| Janssen Scientific Affairs, LLC | $124.99 | 2023 | Tecvayli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.75 | 2021-2024 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $99.56 | 2022-2024 | Fotivda |
| Taiho Oncology, INC. | $94.54 | 2023-2024 | |
| Beone Medicines USA, INC. | $93.73 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $90.87 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $89.87 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $83.52 | 2022-2024 | Empaveli |
| Ipsen Biopharmaceuticals, INC | $76.99 | 2022-2024 | Onivyde, Tazverik, Somatuline Depot |
| Karyopharm Therapeutics INC. | $74.84 | 2023-2024 | Xpovio |
| Adc Therapeutics America, INC. | $63.80 | 2023-2024 | |
| Beigene USA, INC. | $59.39 | 2021-2024 | Brukinsa |
| Secura Bio, INC. | $58.80 | 2021-2023 | Copiktra |
| Recordati_rare_diseases_inc. | $57.47 | 2023-2024 | Sylvant |
| Alnylam Pharmaceuticals INC. | $57.42 | 2024 | Givlaari, Onpattro |
| Stemline Therapeutics INC. | $53.99 | 2023-2024 | Orserdu |
| Genmab U.S., INC. | $52.26 | 2023-2024 | Epkinly |
| Coherus Oncology, INC. | $41.50 | 2023-2024 | |
| Emd Serono, INC. | $40.66 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $39.44 | 2022-2024 | Qinlock |
| Gilead Sciences, INC. | $35.52 | 2023-2024 | |
| Immunogen, INC. | $32.26 | 2023 | Elahere |
| Pharmacosmos Therapeutics INC. | $29.18 | 2024 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $27.85 | 2023 | Libtayo |
| Kite Pharma, INC. | $27.35 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $25.03 | 2022 | |
| Servier Pharmaceuticals LLC | $22.47 | 2024 | |
| Cti Biopharma Corp. | $18.59 | 2022 | |
| Dova Pharmaceuticals | $17.38 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.29 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $15.58 | 2023 | Sancuso |
| Agios Pharmaceuticals, INC. | $14.76 | 2024 | Pyrukynd |
| Organon LLC | $13.78 | 2023 | Ontruzant |
| Epizyme, INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Souchek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.